Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 35 of 36.
Jun 2008
9 Jun · Business
Company through its wholly owned subsidiary - Zydus Healthcare SA PTY. Ltd. is acquiring majority stake of 70% in Simayla Pharmaceuticals of South Africa. As per the agreement reached between the two companies, the remaining stake will be held by the promoter of the Company. In this regard Company has submitted a copy of press release dated June 09, 2008, titled "Zydus acquires majority stake in Simayla Pharmaceuticals of South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
30 May · Business
Press release dated May 30, 2008, titled "Zydus Cadila enters Spain, acquires Laboratorios Combix". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 May · Business
Press release dated May 26, 2008, titled "Zydus Cadila to market Benazepril in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 May · Meeting
In accordance with the provisions of Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution by Postal Ballot) Rules, 2001 the proposed resolution is circulated for approval of the Members of the Company to be accorded by Postal Ballot: Empowering the Board of Directors under Section 293(1)(a) of the Companies Act, 1956. The Company has apppointed Mr. Dilip P. Shah, Practicing Chartered Accountants, as Scrutinizer for conducting the Postal Ballot process. The duly completed postal ballot forms should reach the Scrutinizer on or before the close of the working hours on June 20, 2008. The Scrutinizer will submit his report to the Chairman of the company after completion of the Scrutiny. The results of the voting by Postal Ballot will be announced through a press release on June 30, 2008. A copy of the notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 May · Business
Press release dated May 15, 2008, titled "New Product Approvals for Zydus Cadila from USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
29 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 36940 lacs for quarter ending on 31-MAR-2008 against Rs. 32010 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 3540 lacs for the quarter ending on 31-MAR-2008 against Rs. 3750 lacs for the quarter ending on 31-MAR-2007.29 Apr · Results
Standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 164200 lacs for year ending on 31-MAR-2008 against Rs. 141370 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 23620 lacs for the year ending on 31-MAR-2008 against Rs. 20470 lacs for the year ending on 31-MAR-2007.29 Apr · Updates
Statement of Appropriations pursuant to clause 20 of the Listing Agreement in respect of Annual Audited Financial Results of the Company for the year ended March 31, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Business
Press release dated April 29, 2008, titled "Zydus Cadila's Net Sales up by whopping 27% in FY 08". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Meeting
Register of Members in respect of Equity Shares of the Company shall remain close from July 14, 2008 to July 26, 2008 (both days inclusive) to determine the entitlement of membership of the Company for the payment of dividend as may be declared by the members at the Annual General Meeting of the Company to be held on July 29, 2008 for the year ended March 31, 2008.29 Apr · Dividend
Board of Directors of the Company at its meeting held on April 29, 2008 recommended the declaration of dividend @ 90% i.e. Rs. 4.50 per Equity Share on 12,56,13,708 equity shares of Rs. 5/- each of the Company for the year ended March 31, 2008.29 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 54690 lacs for quarter ending on 31-MAR-2008 against Rs. 42110 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 5200 lacs for the quarter ending on 31-MAR-2008 against Rs. 3890 lacs for the quarter ending on 31-MAR-2007.29 Apr · Results
Consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 226600 lacs for year ending on 31-MAR-2008 against Rs. 178550 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 25760 lacs for the year ending on 31-MAR-2008 against Rs. 23380 lacs for the year ending on 31-MAR-2007.15 Apr · Board meeting
To consider the audited Annual Accounts of the Company for the year ended March 31, 2008 and the Board will consider interalia with other agenda items recommendation of dividend on Equity Shares for the year, 2007 - 08.
Mar 2008
11 Mar · Business
Press release dated March 11, 2008, titled "Zydus and Nycomed expand scope of JV to create an API manufacturing hub for global supplies". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
15 Feb · Business
Press release dated February 15, 2008, titled "Zydus Cadila firms up presence in Oncology segment with Nudoxa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Feb · Business
Press release dated February 04, 2008, titled "Zydus Cadila and Karo Bio of Sweden sign research agreement for a novel drug to treat inflammatory diseases". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
31 Jan · Business
Press release dated January 31, 2008, titled "Zydus Cadila's Income up by 22.7% in Q3". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 40630 lacs for quarter ending on 31-DEC-2007 against Rs. 35440 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 6310 lacs for the quarter ending on 31-DEC-2007 against Rs. 5250 lacs for the quarter ending on 31-DEC-2006.31 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 56140 lacs for quarter ending on 31-DEC-2007 against Rs. 46090 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 5160 lacs for the quarter ending on 31-DEC-2007 against Rs. 6600 lacs for the quarter ending on 31-DEC-2006.24 Jan · Business
Press release dated January 24, 2008, titled "Zydus Cadila and Prolong Pharmaceuticals ink pact for collaboration in Drug Discovery and Development". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jan · Board meeting
To consider apart from other agenda items unaudited financial results for the quarter ended on December 31, 2007.
Dec 2007
31 Dec · Rating
Company has got Credit Rating from CRISIL as under: Rs.300 Million Non-convertible Debenture Programme AA+ (Reaffirmed); Rs.600 Million Commercial Paper Programme P1+ (Reaffirmed)
Oct 2007
26 Oct · Business
Press release dated October 26, 2007, titled "Zydus Cadila registers 28% Income growth in Q2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 44740 lacs for quarter ending on 30-SEP-2007 against Rs. 39070 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 7130 lacs for the quarter ending on 30-SEP-2007 against Rs. 6550 lacs for the quarter ending on 30-SEP-2006.26 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 118190 lacs for half year ending on 30-SEP-2007 against Rs. 92070 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 15400 lacs for the half year ending on 30-SEP-2007 against Rs. 12890 lacs for the half year ending on 30-SEP-2006.26 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 60970 lacs for quarter ending on 30-SEP-2007 against Rs. 47480 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 8010 lacs for the quarter ending on 30-SEP-2007 against Rs. 7050 lacs for the quarter ending on 30-SEP-2006.11 Oct · Board meeting
Meeting on 26 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Sep 2007
25 Sep · Business
Press release dated September 25, 2007, titled "Zydus Cadila receives USFDA approval for Hydroxychloroquine Sulfate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Sep · Business
Press release dated September 06, 2007, titled "Zydus Cadila receives USFDA approval for Carvedilol Tablets Launches product on the very same day". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
30 Aug · Business
Press release dated August 30, 2007, titled "Zydus Cadila files its 5th IND 'ZYH7' a novel drug candidate for treating dyslipidemia and metabolic disorders". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Aug · Meeting
Proceedings of the Annual General Meeting of the Company held on July 31, 2007.The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Aug · Demise
The sad demise of Mr. R. R. Patel proprietor of M/s. R. R. Patel & Co. Chartered Accountants one of the Joint Statutory Auditors of our Company on 12th August 20079 Aug · Dividend
Company shall make the payment of dividend on Equity Shares of the Company for the year ended March 31, 2007 @ 80% i.e. Rs.4/- per Share on 125613708 Equity Shares of the face value of Rs.5/- each as recommended by the Board of Directors from August 06, 2007.
Jul 2007
31 Jul · Business
Press release dated July 31, 2007, titled "Zydus Cadila Q1 Net profit up by 27%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 45230 lacs for quarter ending on 30-JUN-2007 against Rs. 36490 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 6640 lacs for the quarter ending on 30-JUN-2007 against Rs. 4920 lacs for the quarter ending on 30-JUN-2006.31 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 57220 lacs for quarter ending on 30-JUN-2007 against Rs. 44580 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 7390 lacs for the quarter ending on 30-JUN-2007 against Rs. 5840 lacs for the quarter ending on 30-JUN-2006.11 Jul · Board meeting
Meeting on 31 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Jun 2007
27 Jun · Meeting
Cadila Healthcare Limited had informed the Exchange regarding the holding of Annual General Meeting of the Company on July 27, 2007. The Company has now informed the Exchange that: "It has been decided by the directors to reschedule the date of 12th Annual General Meeting of the Company to 31st July, 2007 instead of 27th July 2007 as decided earlier". Further, the Company stated that there would not be any change in the Book Closure of the Company as informed earlier.25 Jun · Business
Press release dated June 25, 2007, titled "Zydus Cadila acquires Brazilian company Nikkho". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jun · Business
Zydus Cadila has entered into an agreement with TGL Enterprises LLC of United States to set up a joint venture company, Zydus Noveltech Inc to develop novel drug delivery based products18 Jun · Issue of FCCBs/ADRs/GDRs
June 17, 2007 that : "The Board of Directors at their meeting held today have decided to issue Foreign Currency Convertible Bonds (FCCBs)/ADRs/GDRs or such other foreign currency instrument upto USD 100 Millions with a Green Shoe Option subject to the approval of shareholders at the ensuing Annual General Meeting and such other approvals, permissions and sanctions as may be required from statutory authorities".13 Jun · Board meeting
To consider amongst other agenda items to issue Foreign Currency Convertible Bonds (FCCBs) / ADRs / GDRs, etc. subject to approval of shareholders and such other statutory authorities.12 Jun · Business
Press release dated June 12, 2007, titled "New Product Approvals for Zydus Cadila from USFDA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Jun · Business
"The Company has received tentative approval for Topiramate Tablets in the strength of 25 mg., 50 mg., and 200 mg. from USFDA". A copy of the press release dated June 06, 2007, titled "Zydus receives tentative approval for Topiramate tablets" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
15 May · Business
"Company has launched 'Slimona' new generation anti-obesity drug in India. Slimona (Rimonabant) is a selective CB1 Endocannabinoid (EC) receptor antagonist indicated for the treatment of obesity". A copy of the press release dated May 15, 2007, titled "Zydus Cadila, the first to launch revolutionary anti-obesity drug Slimona in India" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 May · Business
"The Company has signed Share Purchase Agreement for acquiring 50% equity shares of Sarabhai Zydus Animal Health Limited from its JV Partner Ambalal Sarabhai Enterprises Limited". A copy of the press release dated May 14, 2007, titled "Zydus Cadila buys out JV stake in Sarabhai Zydus Animal Health Ltd" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
26 Apr · Management
At the Board Meeting of the Company held today i.e. April 26, 2007 necessary resolution has been passed to appoint Mr. Sharvil P. Patel, Director of the Company, as Deputy Managing Director for a period of 5 years from 1st April, 2007 subject to the approval of the Members at the ensuing 12th Annual General Meeting of the Company proposed to be held on 27th July, 200726 Apr · Miscellaneous
Statement of Appropriations pursuant to Clause-20 of the Listing Agreement in respect of Annual Audited Financial Results of the Company for the year ended March 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Apr · Meeting
Register of Members in respect of Equity Shares of the Company shall remain closed from July 16, 2007 to July 27, 2007 (both days inclusive) to determine the entitlement of membership of the Company for the payment of dividend as may be declared by the members at the AGM of the Company to be held on July 27, 2007 for the year ended March 31, 2007.